⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 20, 2024Transplantation

Cell-mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multicenter Single-arm Prospective Study

Javier T Solera Victor H. Ferreira Carlos Cervera Seyed M. Hosseini‐Moghaddam John Gill Sarah Shalhoub Jeff Zaltzman Deepali Kumar Atul Humar

View Full Paper

Ask AI

Bookmark

Share

Abstract

There are few interventional studies using CMV cell-mediated immunity (CMI) to guide antiviral prophylaxis. We assessed the Quantiferon-CMV (QTF-CMV) assay to guide CMV prophylaxis duration in high-risk organ transplant recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Solera et al. (2024) studied this question.

synapsesocial.com/papers/68e5b8a1b6db6435875511fa https://doi.org/10.1097/tp.0000000000005173

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cytomegalovirus–Cell‐Mediated Immunity Assays for the Prevention and Management of Cytomegalovirus in Transplant Recipients and Patients Receiving Cellular TherapiesHuman Clinical Trial · 2026
2Evaluation of an Immune-guided Prevention Strategy Against CMV Among Intermediate-risk Kidney Transplant Recipients: A Quasi-experimental StudyCohort Study · 2026
3The Essentials of Cell-Mediated Immunity Assays for the Management of CMV Infection after Solid Organ Transplantation2025
4P-2150. Single Centre Real World Experience of Evaluating Cytomegalovirus Cell Mediated Immunity using an ELISpot Assay in Solid Organ Transplant Recipients: Helpful or Not?Clinical Trial · 2026
5Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients2025 · 4 citations